Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

54.01
-0.0900-0.17%
Post-market: 54.900.8898+1.65%19:51 EDT
Volume:2.14M
Turnover:115.61M
Market Cap:10.10B
PE:-11.94
High:55.28
Open:55.00
Low:53.47
Close:54.10
52wk High:62.40
52wk Low:29.17
Shares:186.93M
Float Shares:158.56M
Volume Ratio:0.87
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5252
EPS(LYR):-3.5776
ROE:-46.61%
ROA:-26.47%
PB:5.41
PE(LYR):-15.10

Loading ...

Revolution Medicines General Counsel Jeff Cislini Reports Disposal of Common Shares

Reuters
·
6 hours ago

Revolution Medicines initiated with an Outperform at Mizuho

TIPRANKS
·
9 hours ago

Revolution Medicines (RVMD) Gets a Buy from Guggenheim

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Celcuity (CELC), Revolution Medicines (RVMD) and Pfizer (PFE)

TIPRANKS
·
Yesterday

Revolution Medicines Inc : Leerink Partners Raises Target Price to $67 From $64

THOMSON REUTERS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences

Reuters
·
Oct 18

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday

Benzinga_recent_news
·
Oct 18

Revolution Medicines rises 11.5%

TIPRANKS
·
Oct 17

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

Benzinga_recent_news
·
Oct 17

Revolution Medicines price target raised to $80 from $78 at BofA

TIPRANKS
·
Oct 17

Shares of Some US Drug Developers up After FDA Announces Recipients of National Priority Vouchers

THOMSON REUTERS
·
Oct 17

Revolution Medicines up 6%, Achieve Life Sciences up 22.1%, Disc Medicine up 19.2%

THOMSON REUTERS
·
Oct 17

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires Live
·
Oct 17

Revolution Medicines Price Target Maintained With a $77.00/Share by Wedbush

Dow Jones
·
Oct 17

'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold'

Benzinga_recent_news
·
Oct 17

BUZZ-U.S. STOCKS ON THE MOVE-Revolution Medicines, Artiva, Jefferies

Reuters
·
Oct 17

S&P 500 Futures Drop In Premarket Trading; Axsome Therapeutics, Bitdeer Techs Lag

Dow Jones
·
Oct 17

BUZZ-Revolution jumps after US FDA adds its drug under new fast-track process

Reuters
·
Oct 17

Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib’s CNPV Designation

TIPRANKS
·
Oct 17

Barclays Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Oct 17